John Tapp
Family Medicine · Bowling Green, KYNPI 1194799676
Payments from drug & device makers
Across 858 payments — averaging $29.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$13K
- Pfizer$2K
- Lilly USA, LLC$924
- AstraZeneca$660
- Novo Nordisk$545
- GSK$471
- plus $7K from 53 others
What the payments were for
- Consulting fees$1,5056%
- Speaking & faculty fees$9,60038%
- Travel & lodging$8723%
- Food & beverage$12,87851%
- Education$2451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,101 in reported general payments places this provider in the 95th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 98 | $139,178 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $90,883 |
| FarxigaDapagliflozin Propanediol | 72 | $73,050 |
| EliquisApixaban | 78 | $65,317 |
| VascepaIcosapent Ethyl | 88 | $54,610 |
| JardianceEmpagliflozin | 47 | $46,257 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $42,941 |
| LinzessLinaclotide | 62 | $41,764 |
| RybelsusSemaglutide | 15 | $37,773 |
| MounjaroTirzepatide | 32 | $37,324 |
| CaplytaLumateperone Tosylate | 16 | $26,128 |
| OzempicSemaglutide | 17 | $21,954 |
| XareltoRivaroxaban | 31 | $18,144 |
| InvokanaCanagliflozin | 12 | $16,256 |
| EntrestoSacubitril/Valsartan | 16 | $15,769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Linzess | $13,038 | $180,942160 claims |
| GSKTrelegy Ellipta | $471 | $90,88390 claims |
| AstraZenecaFarxiga | $660 | $73,05072 claims |
| PfizerEliquis | $2,354 | $65,31778 claims |
| Novo NordiskRybelsus, Ozempic | $545 | $59,72732 claims |
| Boehringer IngelheimJardiance, Tradjenta | $181 | $56,25766 claims |
| Lilly USA, LLCMounjaro | $924 | $37,32432 claims |
| Johnson & JohnsonXarelto, Invokana | $146 | $34,40043 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $194 | $29,53949 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $392 | $26,12816 claims |
| NovartisEntresto | $396 | $15,76916 claims |
| Axsome Therapeutics, Inc.Auvelity | $262 | $14,86123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Bowling Green
- Diego MastronardiBowling Green$196K
- Jane GibsonBowling Green$49K
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.